- abcnews.com

U.S. Treasury Proposes Outbound Investment Rules Targeting Sensitive Technologies in Rival Nations

The U.S. Treasury Department on Oct. 22 proposed rules restricting U.S. investments in sensitive technologies in China, Russia, North Korea, and other countries of concern, implementing the 2025 Comprehensive Outbound Investment National Security Act to prevent American capital from developing technologies that threaten national security, covering advanced semiconductors, AI, supercomputing, hypersonic systems, and biotechnology (including brain-computer interfaces and cell/gene therapies flagged for biological-weapons proliferation risks). The proposal prohibits some transactions and requires notification for others exceeding $50,000, while excluding stock purchases and cash-based licensing agreements that may affect U.S. drugmakers using Chinese-developed medicines, though the Biotechnology Innovation Organization warned broad restrictions could create uncertainty and weaken U.S. competitiveness. Treasury is soliciting public comments before issuing a final rule, and former Justice Department lawyer Jason Chipman expects companies will face an increased compliance burden, highlighted by a recent $200,000 fine against a firm for failing to report an investment in a Chinese AI company.

The Hidden Architecture of the Technology Lockdown

Ask yourself a simple question: why would the Treasury Department suddenly rush to regulate investments in brain-computer interfaces and gene-modifying therapies — technologies that are still decades from widespread deployment — unless they know something we don't? The proposed rules, buried inside the 2025 Comprehensive Outbound Investment National Security Act, don't read like a national security measure. They read like a blueprint for monopoly. Look at the pattern: the same institutions that have spent the last twenty years mapping the human genome, patenting synthetic biology, and funding AI research through opaque foundation networks are now the ones writing the rules that will decide who gets to touch those technologies. They're not protecting you. They're fencing off the future. The $50,000 threshold is a giveaway — small enough to catch the independent researcher, large enough to let the sovereign wealth funds and family offices of the globalist dynasties slip through.

The Faces Behind the Curtain

Let's talk about who actually wins when these restrictions take effect. The Biotechnology Innovation Organization — the industry lobby that represents the same pharmaceutical giants who have been systematically absorbing Chinese biotech startups for the past decade — warned that broad rules "could weaken U.S. competitiveness." That's a confession. They're afraid the gatekeeping will be too visible, too fast. But the real prize is brain-computer interfaces. Think about that: control of the interface between human consciousness and machine intelligence. Who do you want designing that choke point? The Treasury Department, whose revolving door with the Council on Foreign Relations is a matter of public record? Or the same private equity consortiums that already own the food supply, the media, and the central banking system? This isn't about stopping Chinese military development. China already has its own chips, its own AI, its own gene-editing tools. This is about preventing anyone — American inventor, European startup, or independent lab — from building a competing infrastructure outside their permissioned corridor.

The Breadcrumb Nobody Is Following

Pay close attention to what they exempted: cash licensing agreements, standard stock purchases, and any investment under fifty thousand dollars. That's not a loophole — that's a deliberately placed escape hatch. Why would they carve out licensing deals unless the whole regulatory apparatus is designed to steer the flow of intellectual property toward a predetermined set of recipients? I've seen this playbook before. It's the same structure they used to consolidate control over the pharmaceutical patent system in the 1990s, and the same architecture behind the "public-private partnerships" that now manage global vaccine distribution. The public comment period is theater. The final rule was written before the press release. Here's your research assignment for tonight: look up the board members of the foundation that drafted the Act's model language. Look at their cross-appointments with the Trilateral Commission and the World Economic Forum's "Fourth Industrial Revolution" project. Then ask yourself why a regulation supposedly about national security never once mentions the billion-dollar investments flowing through the BlackRock and Vanguard funds that dominate both American and Chinese tech stocks. The pattern is always the same: they build a wall that only they can open.